Your Health, We Care
On March 3, 2021, the U.S. Food and Drug Administration (FDA) expanded the indication approval of Pfizer’s Lorbrena (lorlatinib) to include it as a first-line treatment for anaplastic lymphoma kinase (ALK)-positive metastatic lung cancer.
On November 2, 2018, the U.S. Food and Drug Administration (FDA) approved Lorbrena (generic name: lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have received prior treatment.
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has a···【more】
Release date：2026-01-23Recommended：69
On March 3, 2021, Pfizer announced that the U.S. Food and Drug Administration (F···【more】
Release date：2026-01-23Recommended：81
At the Presidential Symposium of the 2020 ESMO Annual Congress, results of a hea···【more】
Release date：2026-01-23Recommended：63
In December 2020, the U.S. Food and Drug Administration (FDA) accepted a supplem···【more】
Release date：2026-01-23Recommended：70
Pfizer recently announced that the Phase III CROWN study, which evaluates Lorbre···【more】
Release date：2026-01-23Recommended：77
Lorbrena (generic name: Lorlatinib) is a next-generation tyrosine kinase inhibit···【more】
Release date：2026-01-23Recommended：79
On November 19, 2020, Pfizer announced the positive results of the phase III hea···【more】
Release date：2026-01-23Recommended：56
Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) ···【more】
Release date：2026-01-23Recommended：76
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has a···【more】
Release date：2026-01-23Recommended：58
On January 28, 2022, Pfizer Inc. announced that the European Commission (EC) had···【more】
Release date：2026-01-23Recommended：60
